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Abstract
Background: In malaria endemic areas, most people are simultaneously infected with different parasite clones. Detection of
individual clones is hampered when their densities fluctuate around the detection limit and, in case of P. falciparum, by
sequestration during part of their life cycle. This has important implications for measures of levels of infection or for the
outcome of clinical trials. This study aimed at measuring the detectability of individual P. falciparum and P. vivax parasite
clones in consecutive samples of the same patient and at investigating the impact of sampling strategies on basic
epidemiological measures such as multiplicity of infection (MOI).
Methods: Samples were obtained in a repeated cross-sectional field survey in 1 to 4.5 years old children from Papua New
Guinea, who were followed up in 2-monthly intervals over 16 months. At each follow-up visit, two consecutive blood
samples were collected from each child at intervals of 24 hours. Samples were genotyped for the polymorphic markers
msp2 for P. falciparum and msp1F3 and MS16 for P. vivax. Observed prevalence and mean MOI estimated from single
samples per host were compared to combined data from sampling twice within 24 h.
Findings and Conclusion: Estimated detectability was high in our data set (0.79 [95% CI 0.76–0.82] for P. falciparum and,
depending on the marker, 0.61 [0.58–0.63] or 0.73 [0.71–0.75] for P. vivax). When genotyping data from sequential samples,
collected 24 hours apart, were combined, the increase in measured prevalence was moderate, 6 to 9% of all infections were
missed on a single day. The effect on observed MOI was more pronounced, 18 to 31% of all individual clones were not
detected in a single bleed. Repeated sampling revealed little difference between detectability of P. falciparum and P. vivax.
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Introduction
Detection of malaria parasites is essential for many malariolog-
ical investigations. For instance, the detailed maps of global
malaria risk created by the Malaria Atlas Project (MAP) use
parasite prevalence as the main indicator for transmission
[1,2,3,4]. Prevalence is also the key malariological measure
assessed in Malaria Indicator Surveys (MIS) [5,6]. Within
populations, the identification of individual parasite clones by
PCR based genotyping techniques has substantially increased
knowledge of the infection dynamics of malaria by providing
estimates of multiplicity of infection, incidence and clearance rates
[7,8,9,10]. In addition, it allows classification of drug failures into
recrudescences and new infections.
However, all DNA based techniques for detection of malaria
parasites in a blood sample are imperfect. Parasites can remain
undetected because their densities fall below the detection limit of
the diagnostic technique. PCR based methods generally have a
better detection limit compared to microscopy [11], but both
methods likely miss a proportion of clones.
Several biological factors add to the probability of low numbers
of parasite in the blood stream and subsequently of missing clones.
In P. Falciparum infections late blood stage forms cytoadhere to the
endothelial wall of blood vessels. This sequestration of P. Falciparum
in deep organs lasts for 24–28 hrs of the 48 hrs blood stage cycle.
During this period parasites are absent from the peripheral
circulation and escape detection. A parasite clone defined by a
shared genotype and by common ancestry is completely absent
only if all individual parasites belonging to this brood are tightly
synchronized. By rare chance a clone might be superinfected by
another clone sharing the same genotype. The probability of this
occurring is determined by the resolution of the typing scheme and
the mean multiplicity of infection in the study area [12].
In blood stage schizogony a single schizont divides into
numerous merozoites [13] within a few hours. This has particular
implications for P. Vivax, because these parasites usually divide
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synchronously. As a result the number of DNA copies of a given
clone may drastically increase from one day to another. In
addition, parasite densities of P. Vivax are usually lower than those
of P. Falciparum [14,15]. Taken these factors together, imperfect
detection of P. Vivax clones is likely, however, only for P. Falciparum
this has been suspected because of sequestration.
Besides these issues of parasite biology, also methodological
constraints may add to the risk of missing clones. These causes
equally apply for both parasite species. In multi-clonal infections
minority variants constituting a small proportion of the total
parasite load, might be missed by PCR-based detection, because in
competition for primers or other constituents of the reaction mix,
they are outcompeted by the more abundant clones.’’
Although sequestration of P. Falciparum has been reported
several decades ago [16,17], low parasite densities in P. Vivax and
the sensitivity threshold of both light microscopy and PCR-based
diagnostic methods have been well studied [18,19,20], the
consequences of imperfect detectability for estimates of prevalence
and other epidemiological parameters have often not been
addressed adequately.
The daily dynamics of P. Falciparum clones has been investigated
previously in a longitudinal study with daily follow up bleeds
collected over a period of 14 days from 20 children from Tanzania
[21]. A complex dynamics of P. Falciparum clones was observed.
The composition of infecting clones found in a single host was
found to be unstable over time or even changing from one day to
another [21]. In a drug efficacy trial in Tanzania children were
sampled on two consecutive days and the results were compared to
the standard protocol with single bleeds. An increased number of
multiple clone infections and additional recrudescence cases were
detected [22]. Several studies have described statistical models to
estimate infection dynamics of P. Falciparum allowing for this
imperfect detection [23,24,25,26]. The model by Sama et al. [23]
was applied for a longitudinal field study in Ghana, where blood
samples were collected once at each of 6 cross sectional surveys
conducted in 2-monthly intervals. Statistical models indicated that
at any time of sampling on average only 47% of all parasite clones
present in a host were detected by genotyping [23].
Back in 1966 Garnham reported a slight tendency of late P.
Vivax stages to retreat from the peripheral circulation [27], but
sequestration is generally thought to be absent in P. Vivax. This
view was questioned only recently when cytoadherence of P. Vivax
was shown in vitro [28]. Few studies have addressed the infection
dynamics of individual P. Vivax clones [7]. Daily fluctuations in
detectability of P. Vivax clones have not yet been investigated.
To obtain a more precise picture of the parasite population
present in a host, blood sampling should be repeated within short
time intervals. However, collection of consecutive blood samples
from a study participant will translate into considerably increased
efforts in the field and laboratory, added costs, and additional
discomfort for participants. Limited knowledge has been gathered
so far on the effect of such a sampling scheme on epidemiological
measures, such as prevalence or multiplicity of infection.
Here we present data from a large set of paired samples that
were collected 24 hours apart. Within this time interval re-
infection with a new parasite clone is very unlikely and may be
ignored. Samples were derived from a cohort study performed in
Papua New Guinean children 1 to 4.5 years of age living in an
area highly endemic for both P. Falciparum and P. Vivax. Parasites
of both species were genotyped to calculate the detectability of
infection and to investigate the benefit of collecting 24 h bleeds on
basic and molecular measures of epidemiology such as prevalence
and multiplicity of infection. Figure 1 gives a schematic overview
on the effect of combining results obtained on two consecutive
days.
Methods
Ethics Statement
Scientific approval and ethical clearance for the study was
obtained from the Medical Research and Advisory Committee
(MRAC) of the Ministry of Health in PNG and from the
Ethikkommission beider Basel in Switzerland. Informed written
consent was sought from all parents or guardians prior to
recruitment of each child.
Field survey and patients
This study was conducted in a rural area near Maprik, East
Sepik Province, Papua New Guinea. A detailed description of the
study was given previously [15]. Briefly, 269 study participants
were enrolled at an age of 1 to 3 years starting in March 2006 and
regular follow-up visits were conducted over a period of 16 months
until July 2007. At seven time points separated by 8-weekly
intervals two consecutive 250 ml finger prick blood samples were
Figure 1. Dynamics of parasite clones over 24 hours. Schematic overview of possible outcomes of 24 h bleeds. A sample is positive as soon as
a parasite is detected on either day. Different colors of PCR results indicate different clones detected. The combined multiplicity of infection includes
all clones detected in two corresponding bleeds.
doi:10.1371/journal.pone.0019010.g001
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collected at intervals of 24 hours (in the following termed: 24 h
bleed) from each study participant. Two blood slides were made
and a rapid diagnostic test was performed upon presentation of
malaria symptoms. Antimalarial treatment with CoartemH
(Novartis, Switzerland) was administered upon a positive test plus
iron and folate supplementation if haemoglobin levels were
,7.5 g/dl. Children that were treated on day 1 of the 24 h bleed
were excluded from the analysis (n = 97). Over the 16 months
follow up period, study participants adhered to 93 to 94% of all
study visits.
Laboratory procedures
Diagnosis of the different malaria species was performed in
parallel by two methods, light microscopy (LM) and post-PCR
Ligase Detection Reaction (LDR) [29]. Only samples positive by
light microscopy and/or LDR were genotyped for our markers.
All finger prick blood samples were separated into plasma and
cells. DNA was extracted from cell pellets using QIAampH 96
DNA Blood Kit (Qiagen, Australia) according to the manufactur-
er’s instructions. All samples were genotyped for the polymorphic
marker gene merozoite surface protein 2 (msp2) by use of capillary
electrophoresis (PCR-CE) for fragment sizing as previously
described by Falk et al. [18] with some minor changes and
adaptations of PCR conditions for highly purified DNA as
described by Schoepflin et al. [12].
P. vivax genotyping was performed as described previously [30]
with the following modifications: A multiplex primary PCR was
done with the primers for the 2 markers msp1F3 and MS16
followed by individual nested PCRs for msp1F3 and MS16.
Primary PCR was performed in a volume of 20 ml containing 1 ml
template DNA, 0.25 mM of each primer (Eurofins MWGOperon),
0.3 mM dNTPs (Solis BioDyne), 2 mM MgCl2, 2 ml Buffer B
(Solis BioDyne) and 5 U Taq FIREPol (Solis BioDyne). 1 ml
primary PCR product was used as template for nested PCR
performed in a volume of 20 ml containing 0.25 mM of each
primer (Applied Biosystems), 0.2 mM dNTPs (Solis BioDyne),
2 mM MgCl2, 2 ml Buffer B (Solis BioDyne) and 1.5 U Taq
FIREPol (Solis BioDyne). The forward primers for the nested
PCR were labelled with fluorescent dyes: 6-FAM for msp1F3, NED
for MS16. Cycling conditions were as follows: Initial denaturation
95uC for 1 minute, then 30 cycles (primary PCR) or 25 cycles
(nested PCR) with 15 seconds denaturation at 95uC, 30 seconds
annealing at 59uC and 30 seconds elongation at 72uC plus a final
elongation of 5 minutes at 72uC.
All samples negative after the first round of PCR amplification
were repeated once. Repeats and all microscopy negative samples
(due to an expected lower parasitaemia) were done under similar
conditions with the exception that 2 ml DNA solution were used as
template for the primary PCR. Capillary electrophoresis was done
as described earlier [30]. As the msp1F3 nested PCR in general led
to more amplification product compared to the MS16 PCR, twice
as much MS16 PCR product (2.5 ml of 1:10 dilution of PCR
product) was analysed by capillary electrophoresis.
All alleles were grouped into bins of 3 base pairs according to
the possible size of insertions and deletions in coding regions and
the repeat size of the microsatellite.
Data analysis
Analysis of 24 h interval bleeds. Sample pairs collected
24 hours apart from the same patient were compared. Sample
pairs were excluded from the analysis if antimalarial treatment was
given on the first day of paired sampling. Individual genotypes
were classified by positivity on each of two consecutive days,
leading to two categories for each genotype: one day positive
(genotype observed on either day of paired sampling, n1) and both
days positive (n2). An estimate ~q of the detectability q was
calculated as suggested by Bretscher et al. [31]:
~q~
2n2
n1z2n2
An approximate confidence interval was calculated as follows: CI
[q61.96 se(q)], where the standard error is:
se(q)~
2
ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
n1n2(n1zn2)
p
(n1z2n2)
2
Comparison of detectability between day 1 and day 2 was done by
McNemar’s exact test for paired data. Detectability was calculated
for different age groups of patients, for samples with different MOI
(combined over 24 h) and for different parasite densities at day 1.
Comparison of different groups was done by nonparametric test
for trend across ordered groups. Statistical analysis was performed
using STATAH 9.1 statistical analysis software (Stata Corporation,
College Station, TX).
Results
Parasite detection by light microscopy and PCR-capillary
electrophoresis
For the analysis of paired samples collected in 24 h interval,
1019 pairs, equal to 2038 individual blood samples, were eligible.
LM diagnosed P. falciparum in 398 samples, in 362 samples (91%)
this was confirmed by PCR-CE. Additional 210 microscopy-
negative samples were P. falciparum positive by PCR-CE, leading to
a total of 572 samples for which P. falciparum genotyping results
were obtained. P. vivax was diagnosed in 1001 samples by LM, 987
(98.6%) of them were also positive by PCR-CE. Additional 187
samples were positive by PCR-CE, leading to a total of 1174 blood
samples with P. vivax genotyping results. Thus, sensitivity of LM
was lower than that of PCR based diagnosis. Detection of P. vivax
by MS16 PCR (1161 positive samples) was more sensitive than by
msp1F3 PCR (1120 positive samples). This difference was
significant (McNemar’s test: x2 = 9.48, p = 0.002).
Effect of repeated sampling on observed parasite
prevalence
By light microscopy 242 and 563 out of 1019 pairs were positive
for P. falciparum and P. vivax, respectively, at least on either day
(Table 1). Observed prevalence did not differ between individual
days but it increased when both days were combined. P. falciparum
parasites were detected in 19.1% of samples at day 1 and 20.0% at
day 2 (McNemar’s test: x2 = 0.65, p = 0.42). Overall, parasites
were detected in 23.7% of sample pairs. Observed prevalence of P.
vivax was 48.6% on day 1 and 49.7% on day 2 (McNemars test:
x2 = 0.88, p = 0.35), and 55.3% when both days were combined.
The 1019 sample pairs were genotyped using msp2 as marker for
P. falciparum and both msp1F3 and MS16 as markers for P. vivax.
After PCR the number of pairs positive at least on one of both
consecutive days increased to 311 for P. falciparum and 616 for P.
vivax. Table 1 summarizes the detection of parasites by PCR on
day 1 and 2 of paired samples. Again the observed prevalence of P.
falciparum as well as P. vivax infection did not differ significantly
between both days (P. falciparum: 27.8% on day 1 vs. 28.5% on day
2, McNemar’s test: x2 = 1.0, p= 0.3; P. vivax: 58.5% on day 1 vs.
60.5% on day 2, McNemar’s test: x2 = 2.21, p= 0.14). When
typing results from both days were combined, the observed
Probability of Detection of Human Plasmodia
PLoS ONE | www.plosone.org 3 April 2011 | Volume 6 | Issue 4 | e19010
prevalence increased only marginally: from 28% to 30.6% for P.
falciparum and from 59.3% to 64.0% for P. vivax.
Effect of repeated sampling on detection of individual
clones
When assessing the persistence of individual alleles on the
consecutive days of sampling, considerable turn-over in allele
composition was observed (Table 2). Examples from 2 patients are
given in Figure 2. For P. falciparum msp2 64.7% of the infecting
clones were observed on both days. For P. vivax, 57.0% of the
msp1F3 alleles and 43.5% of the MS16 alleles were observed on
both consecutive days. These two markers differed slightly in their
genetic diversity, with MS16 (virtual heterozygosity HE= 0.98)
showing greater polymorphism than msp1F3 (HE= 0.88).
Combining the genotyping results from 24 h bleeds made it
possible to assess the effect of repeated sampling on other
molecular epidemiological parameters, i.e. prevalence and MOI.
In P. falciparum combining results from both days lead to a small
increase in observed mean MOI to 1.68 compared to an observed
mean MOI of 1.52 at day 1. In P. vivax the observed mean MOI
based on msp1F3 increased from 2.21 detected on a single day to
2.60 detected on two days. For the more diverse marker MS16, the
observed mean MOI increased from 2.43 to 3.10. When both
markers were considered to establish mean MOI, i.e. for each pair
the highest number of clones observed was counted, observed
MOI increased from 2.78 based on a single day bleed to 3.37
based on results of both consecutive days (Table 2).
Detectability, ~q, was in the same range for both Plasmodium
species: for P. falciparum clones detectability was 0.79 and for P.
vivax detectability was 0.73 based on msp1F3 marker and 0.61
based on microsatellite MS16.
The relationship of clone detectability with age, MOI and
parasite density was determined. Figure 3 depicts detectability by
age group (0–2 years, 2–3 years, .3 years) for light microscopy
and PCR-CE detection. No major difference was observed except
for P. vivax detection by microsatellite marker MS16, which
revealed a slightly lower detectability in children above 3 years
compared to younger children (no overlap of 95% CI).
The influence of MOI on detectability was investigated
(Figure 4). All markers showed a significant decrease in
detectability with increasing MOI (nonparametric test for trend
across groups, P. falciparum msp2: z =24.36, P,0.001; P. vivax
msp1F3: z =23.72, P,0.001; P. vivax MS16: z =24.82, P,0.001).
Detectability increased with parasite density for both parasite
species (Figure 5). P. falciparum msp2 detectability increased with
increasing density. P. vivax detectability increased with density until
5000 to 10’000 parasites/ml and decreased thereafter. In samples
negative by LM detectability was very low, 0.69 for P. falciparum
msp2, 0.48 for P. vivax msp1F3 and 0.36 for P. vivax MS16.
Discussion
Genotyping of malaria parasites has become an integral part
of many malariological field studies. Since more than a decade
genotyping has been considered imperative for clinical trials of
antimalarials performed in endemic countries, The hallmark of
PCR correction of clinical trial outcomes is discrimination of
new infections versus recrudescences. Quantification of clone
detectability at any time point of blood sampling contributes
relevant information on the reliability of PCR corrections.
Furthermore, the number of newly acquired clones per time
interval might be a suitable outcome measurement of antima-
larial interventions; the parameter ‘‘clone detectability’’ might
also correct this estimate.
Imperfect detectability for P. falciparum has been common
knowledge, but to date this effect has been quantified only in few
molecular epidemiological studies. The detectablity of P. vivax
clones has been largely ignored due to the reported absence of
sequestration. However, the generally lower parasite densities in P.
vivax compared to P. falciparum has potential to contribute to
compromised detectablity in a major way. The precise estimation
of the detection probabilities of both species, undertaken in the
Table 1. Effect of repeated sampling on P. falciparum and P. vivax prevalence by light microscopy or PCR.
P. falciparum P. falciparum P. vivax P. vivax P. vivax P. vivax
Microscopy msp2 PCR Microscopy msp1F3 PCR MS16 PCR
PCR 2
markers1
No. of positive samples
1st day pos., 2nd day neg. 39 (16.1%) 21 (6.8%) 57 (10.1%) 39 (6.3%) 49 (7.8%) 40 (6.1%)2
1st day neg., 2nd day pos. 47 (19.4%) 28 (9.0%) 68 (12.1%) 56 (9.1%) 58 (9.1%) 55 (8.4%)3
Both days positive 156 (64.5%) 262 (84.2%) 438 (77.8%) 521 (84.6%) 527 (83.1%) 557 (85.5%)
Total no. of pairs positive at least on one day 242 311 563 616 634 652
Prevalence (parasite positivity)
Prevalence on 1st day (n = 1019 samples) 0.19 (195/1019) 0.29 (283/1019) 0.49 (495/1019) 0.55 (560/1019) 0.57 (576/1019) 0.59
(597/1019)
Prevalence on 2nd day (n = 1019 samples) 0.20 (203/1019) 0.28 (290/1019) 0.50 (506/1019) 0.57 (577/1019) 0.57 (585/1019) 0.60
(612/1019)
Prevalence 2 days combined (n = 1019 pairs) 0.24 (242/1019) 0.31(311/1019) 0.55 (563/1019) 0.60 (616/1019) 0.62 (634/1019) 0.64
(652/1019)
Detectability ~q [95% CI] 0.78 [0.74–0.83] 0.91 [0.89–0.94]4 0.88 [0.86–0.89] 0.92 [0.90–0.93]4 0.91 [0.89–0.93]4 0.92
[0.91–0.94]4
1A sample was defined positive for P. vivax if any of the two markers msp1F3 or MS16 was amplified.
2These samples are positive on day 1 for at least one marker and negative on day 2 for both markers.
3These samples are negative on day 1 for both markers and positive on day 2 for at least one marker.
4Detectability refers to PCR positivity at day 1 versus day 2.
doi:10.1371/journal.pone.0019010.t001
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same field study and under perfectly matching experimental
conditions, allows assessing the combined effects of parasite
sequestration, synchronicity and low parasitaemia and differences
among Plasmodium species. It is clear that the individual factors,
contributing jointly to detectability, cannot be determined by our
genotyping approach.
Our analysis of samples collected 24 hours apart revealed
limited day-to-day fluctuations in the detection of P. falciparum and
P. vivax infection. This indicates that short-term sampling has only
a small impact on prevalence estimates – regardless of whether
infections are detected by light microscopy or PCR. For both
species the observed prevalence by PCR increased, when 2 days
were combined, by less than 10%. A more pronounced difference
in prevalence based on one versus two days of sampling was only
observed for microscopic detection of P. falciparum, where
prevalence increased by 24%. It is unclear in how far the effect
Figure 2. Examples of results obtained on two consecutive days by PCR-capillary electrophoresis. Capillary electrophoresis
chromatograms obtained with the P. vivax marker msp1F3 from two patients on two consecutive days. X-axis: size of PCR product in base pairs.
Y-axis: relative fluorescent units. In patient 1 one clone was detected on day 1, and two additional clones were detected on day 2, combined MOI= 3.
Patient 2 was negative on day 1, but one clone was found on day 2, combined MOI = 1.
doi:10.1371/journal.pone.0019010.g002
Table 2. Effect of repeated sampling on molecular detection of parasite clones and on multiplicity of infection.
P. falciparum P. vivax P. vivax P. vivax
msp2 msp1F3 MS16
2 markers
combined1
Detection of parasite clones
No. clones detected only on day 1 93 (18.0%) 382 (23.8%) 495 (25.2%)
No. clones detected only on day 2 90 (17.4%) 307 (19.2%) 617 (31.3%)
No. clones detected on both days 335 (64.7%) 912 (57.0%) 855 (43.5%)
Total No. of clones 518 1601 1967
Detectability ~q [95% CI] 0.79 [0.76–0.82]2 0.73 [0.71–0.75]2 0.61 [0.58–0.63]2
Multiplicity of infection
MOI on day 1 1.53 2.31 2.34 2.78
MOI on day 2 1.47 2.11 2.52 2.77
MOI on both days 1.68 2.60 3.10 3.37
1The highest value for MOI of either marker msp1F3 or MS16 was used.
2Detectability refers to individual genotypes at day 1 versus day 2.
doi:10.1371/journal.pone.0019010.t002
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of parasite synchronization and sequestration add to this
discrepancy between PCR and microscopy in P. falciparum
detectability. These finding suggests that for Plasmodium species
conducting repeated sampling within 24 h does not substantially
increase the observed prevalence.
Detection of individual clones was very high in P. falciparum
(~q=0.79). Accordingly, combining genotypes from both days
resulted in a small increase in observed mean MOI rising from
1.52 based on one day to 1.68 for both days. Children ,5 years
have not yet developed a strong immunity to P. falciparum [15] and
therefore carry high parasite densities (mean parasite density: 2558
parasites/ml), which leads to a better chance to detect by PCR
most of the parasite clones present. Recently in a similar study in
Ghana blood samples from individuals up to 20 years were
repeatedly collected in intervals of 1, 4, 5 and 7 days [31].
Detectability was calculated using the same approach as in our
study. Clone detectability was around 0.6 in sample pairs collected
24 hours apart [31].
In contrast to P. falciparum, sequestration of late stage parasites
has not been reported from P. vivax. Despite this biological
difference, the detectability of individual parasite clones was lower
in P. vivax than in P. falciparum. A larger number of P. vivax clones
was only detected on either day for both P. vivax markers analyzed.
In P. vivax parasite densities are generally much lower than in P.
falciparum, in our study mean P. vivax density was 498 parasites/ml
compared to the 5-fold higher P. falciparum density. Our results
suggest that the overall low parasitaemia combined with
synchronized replication, as generally seen in P. vivax, has a larger
impact on detectability than sequestration plus sporadic low
parasitaema, as observed in P. falciparum.
The number of concurrent P. falciparum or P. vivax infections had
a pronounced effect on detectability: Increasing MOI lead to
decreasing detectability. It has been suggested that in multiple-
clone infections, clones representing a minority of the total parasite
population in a host might escape detection by PCR [32]. In
experimental mixtures of DNA from two different P. falciparum
clones up to ratios of 1:100, both genotypes were detected by
PCR-CE [33], as well as in mixtures of DNA from two different P.
falciparum clones in a ratio of 1:5 [34]. However, our observation
that detectability decreased with increasing MOI, suggests
impaired amplification of minority clones. Hence, the higher
Figure 3. Detectablity of Plasmodium infections and parasite clones in different age groups. Values for microscopy and ‘‘P. vivax PCR any
marker’’ refer to detection of parasites without distinction of clones. Values for the molecular markers P. falciparum msp2, P. vivax msp1F3 and P. vivax
MS16 refer to the detection of parasite clones. Larger 95% CI of P. falciparum detectability are mainly caused by smaller sample size.
doi:10.1371/journal.pone.0019010.g003
Figure 4. Detectablity of parasite clones vs. multiplicity of
infection.
doi:10.1371/journal.pone.0019010.g004
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mean MOI in P. vivax (MOI= 3.37) compared to P. falciparum
(MOI= 1.68) could be seen as a further reason for the slightly
lower detectability in P. vivax.
Detectability of the two P. vivax markers msp1F3 (~q=0.73) and
MS16 (~q=0.61) differed. Overall, more samples were positive for
P. vivax and more clones were detected with the MS16 PCR. This
suggests a higher detection threshold of the msp1F3 PCR in
combination with a lower influence of fluctuations in parasite
density on detectability. In addition, a difference in the genetic
diversity of these markers could add to the discrepant values: two
independent clones are expected to share more often the same
msp1F3 allele.
Our results highlight that a single bleed does not reflect the full
complexity of concurrently infecting P. vivax clones. The true MOI
of P. vivax is underestimated to a greater extent than the MOI of P.
falciparum. The effect of repeated sampling on prevalence,
however, was in the same range in P. falciparum and P. vivax: for
both species 6 to 9% of all infections were missed on any single
day. The known biology suggests that low parasite densities should
have different causes in P. falciparum and P. vivax. P. falciparum
parasites sequester periodically but a clone is absent from the
peripheral circulation only if its erythrocytic cycle is tightly
synchronized, which according to our data seems not to be the
rule. P. vivax generally occurs at lower densities, and the timing of a
parasite clone within the erythrocytic cycle seems to be well
synchronized. These are major differences between both species,
but with respect to detectability of parasite clones in the blood
stream, both species differ less than previously thought.
In our study participants parasite densities for P. vivax dropped
with increasing age, while for P. falciparum densities remained at
the same level [15]. If parasite densities would directly impact
detectability, a similar decrease in detectability with increasing age
would thus be expected for P. vivax. However, we did not observe a
clear effect of parasite density or age on detectability. Despite the
fact that we did not detect an age trend in detectability in our
study participants aged 1 to 4.5 years, this relationship might be
different in older individuals. It remains open whether the often
observed decrease of prevalence over the entire age range in
moderate to high levels of transmission might be due at least
partially to lower detectability associated with decreasing parasite
densities.
Our P. falciparum results were generated by using a similar
experimental and analytical approach as in a previous study,
conducted in a highly endemic area in Ghana, and results can thus
be compared. When all age groups were included in the Ghana
study a strong age-dependency of detectability was noted, with a
detectability of over 60% in younger individuals and only 10% in
adults [24]. Overall, only 35% of all clones present in the host
were detected in a single blood sample [18]. In individuals of the
same age group as our participants, detectability ranged from 0.51
to 0.55 [31]. This lower detectability in Ghana could be affected
by higher malaria endemicity and higher mean MOI. A lower
transmission and therefore slower acquisition of immunity in PNG
might lead to lower age dependency in detectability. It remains
open whether in older children the often-observed decrease of
prevalence by age in moderate to high levels of transmission might
be due at least partially to lower detectability associated with
decreasing parasite densities. Our current results reflect the
situation in children harbouring high parasite densities. The
situation in adults might be different.
In conclusion, when both 24 h bleeds were combined, we
observed an increase in precision of estimates of epidemiological
parameters in our study for both P. falciparum and P. vivax. While
the increase in observed prevalence was limited, the effect on
detection of individual alleles was more pronounced. Especially in
highly endemic countries where most patients carry multiple clone
infections repeated sampling substantially increases the precision
of observed epidemiological parameters such as MOI. There was
surprisingly little difference between the two parasites; just as
studies of P. falciparum should recognize that they only detect a
proportion of infections, the same is true for P. vivax.
Acknowledgments
We are grateful to the study participants and their parents or guardians,
and to the IMR field team and microscopists. We thank two anonymous
reviewers for their comments on the manuscript.
Author Contributions
Conceived and designed the experiments: IF IM TAS PAZ PS. Performed
the experiments: CK SS EL BK. Analyzed the data: CK SS MB TAS.
Wrote the paper: CK SS IF.
Figure 5. Detectablity of parasite clones in patients harbouring
different parasite densities.
doi:10.1371/journal.pone.0019010.g005
Probability of Detection of Human Plasmodia
PLoS ONE | www.plosone.org 7 April 2011 | Volume 6 | Issue 4 | e19010
References
1. Guerra CA, Hay SI, Lucioparedes LS, Gikandi PW, Tatem AJ, et al. (2007)
Assembling a global database of malaria parasite prevalence for the Malaria
Atlas Project. Malar J 6: 17.
2. Hay SI, Guerra CA, Gething PW, Patil AP, Tatem AJ, et al. (2009) A world
malaria map: Plasmodium falciparum endemicity in 2007. PLoS Med 6:
e1000048.
3. Guerra CA, Howes RE, Patil AP, Gething PW, Van Boeckel TP, et al. (2010)
The international limits and population at risk of Plasmodium vivax transmission
in 2009. PLoS Negl Trop Dis 4: e774.
4. Patil AP, Okiro EA, Gething PW, Guerra CA, Sharma SK, et al. (2009)
Defining the relationship between Plasmodium falciparum parasite rate and
clinical disease: statistical models for disease burden estimation. Malar J 8: 186.
5. Thuilliez J (2010) Fever, malaria and primary repetition rates amongst school
children in Mali: combining demographic and health surveys (DHS) with spatial
malariological measures. Soc Sci Med 71: 314–323.
6. Jensen TP, Bukirwa H, Njama-Meya D, Francis D, Kamya MR, et al. (2009)
Use of the slide positivity rate to estimate changes in malaria incidence in a
cohort of Ugandan children. Malar J 8: 213.
7. Bruce MC, Galinski MR, Barnwell JW, Donnelly CA, Walmsley M, et al. (2000)
Genetic diversity and dynamics of plasmodium falciparum and P. vivax
populations in multiply infected children with asymptomatic malaria infections
in Papua New Guinea. Parasitology 121(Pt 3): 257–272.
8. Daubersies P, Sallenave-Sales S, Magne S, Trape JF, Contamin H, et al. (1996)
Rapid turnover of Plasmodium falciparum populations in asymptomatic
individuals living in a high transmission area. Am J Trop Med Hyg 54: 18–26.
9. Schoepflin S, Lin E, Kiniboro B, DaRe JT, Mehlotra RK, et al. (2010)
Treatment with coartem (artemether-lumefantrine) in Papua New Guinea.
Am J Trop Med Hyg 82: 529–534.
10. Nsanzabana C, Hastings IM, Marfurt J, Muller I, Baea K, et al. (2010)
Quantifying the evolution and impact of antimalarial drug resistance: drug use,
spread of resistance, and drug failure over a 12-year period in Papua New
Guinea. J Infect Dis 201: 435–443.
11. Okell LC, Ghani AC, Lyons E, Drakeley CJ (2009) Submicroscopic infection in
Plasmodium falciparum-endemic populations: a systematic review and meta-
analysis. J Infect Dis 200: 1509–1517.
12. Schoepflin S, Valsangiacomo F, Lin E, Kiniboro B, Mueller I, et al. (2009)
Comparison of Plasmodium falciparum allelic frequency distribution in different
endemic settings by high-resolution genotyping. Malar J 8: 250.
13. Sherman IW (1998) Malaria : parasite biology, pathogenesis, and protection.
Washington, DC: ASM Press. xiii, 575 p.
14. Bruce MC, Donnelly CA, Packer M, Lagog M, Gibson N, et al. (2000) Age- and
species-specific duration of infection in asymptomatic malaria infections in
Papua New Guinea. Parasitology 121(Pt 3): 247–256.
15. Lin E, Kiniboro B, Gray L, Dobbie S, Robinson L, et al. (2010) Differential
patterns of infection and disease with P. falciparum and P. vivax in young Papua
New Guinean children. PLoS One 5: e9047.
16. Miller LH (1969) Distribution of mature trophozoites and schizonts of
Plasmodium falciparum in the organs of Aotus trivirgatus, the night monkey.
Am J Trop Med Hyg 18: 860–865.
17. Bignami A. BG (1890) Osservazioni suile febbri malariche estive-autunnall. La
Riforma Medica 232: 1334–1335.
18. Falk N, Maire N, Sama W, Owusu-Agyei S, Smith T, et al. (2006) Comparison
of PCR-RFLP and Genescan-based genotyping for analyzing infection dynamics
of Plasmodium falciparum. Am J Trop Med Hyg 74: 944–950.
19. Liu S, Mu J, Jiang H, Su XZ (2008) Effects of Plasmodium falciparum mixed
infections on in vitro antimalarial drug tests and genotyping. Am J Trop Med
Hyg 79: 178–184.
20. Ochola LB, Vounatsou P, Smith T, Mabaso ML, Newton CR (2006) The
reliability of diagnostic techniques in the diagnosis and management of malaria
in the absence of a gold standard. Lancet Infect Dis 6: 582–588.
21. Farnert A, Snounou G, Rooth I, Bjorkman A (1997) Daily dynamics of
Plasmodium falciparum subpopulations in asymptomatic children in a
holoendemic area. Am J Trop Med Hyg 56: 538–547.
22. Martensson A, Ngasala B, Ursing J, Isabel Veiga M, Wiklund L, et al. (2007)
Influence of consecutive-day blood sampling on polymerase chain reaction-
adjusted parasitological cure rates in an antimalarial-drug trial conducted in
Tanzania. J Infect Dis 195: 597–601.
23. Sama W, Owusu-Agyei S, Felger I, Vounatsou P, Smith T (2005) An
immigration-death model to estimate the duration of malaria infection when
detectability of the parasite is imperfect. Stat Med 24: 3269–3288.
24. Sama W, Owusu-Agyei S, Felger I, Dietz K, Smith T (2006) Age and seasonal
variation in the transition rates and detectability of Plasmodium falciparum
malaria. Parasitology 132: 13–21.
25. Smith T, Vounatsou P (2003) Estimation of infection and recovery rates for
highly polymorphic parasites when detectability is imperfect, using hidden
Markov models. Stat Med 22: 1709–1724.
26. Hill WG, Babiker HA (1995) Estimation of numbers of malaria clones in blood
samples. Proc Biol Sci 262: 249–257.
27. Garnham PCC (1966) Malaria Parasites And Other Heamosporidia. Oxford:
Blackwell Scientific Publications.
28. Carvalho BO, Lopes SC, Nogueira PA, Orlandi PP, Bargieri DY, et al. (2010)
On the Cytoadhesion of Plasmodium vivax-Infected Erythrocytes. J Infect Dis.
29. McNamara DT, Kasehagen LJ, Grimberg BT, Cole-Tobian J, Collins WE, et al.
(2006) Diagnosing infection levels of four human malaria parasite species by a
polymerase chain reaction/ligase detection reaction fluorescent microsphere-
based assay. Am J Trop Med Hyg 74: 413–421.
30. Koepfli C, Mueller I, Marfurt J, Goroti M, Sie A, et al. (2009) Evaluation of
Plasmodium vivax genotyping markers for molecular monitoring in clinical
trials. J Infect Dis 199: 1074–1080.
31. Bretscher MT, Valsangiacomo F, Owusu-Agyei S, Penny MA, Felger I, et al.
(2010) Detectability of Plasmodium falciparum clones. Malar J 9: 234.
32. Juliano JJ, Gadalla N, Sutherland CJ, Meshnick SR (2010) The perils of PCR:
can we accurately ‘correct’ antimalarial trials? Trends Parasitol 26: 119–124.
33. Liljander A, Wiklund L, Falk N, Kweku M, Martensson A, et al. (2009)
Optimization and validation of multi-coloured capillary electrophoresis for
genotyping of Plasmodium falciparum merozoite surface proteins (msp1 and 2).
Malar J 8: 78.
34. Havryliuk T, Orjuela-Sanchez P, Ferreira MU (2008) Plasmodium vivax:
microsatellite analysis of multiple-clone infections. Exp Parasitol 120: 330–336.
Probability of Detection of Human Plasmodia
PLoS ONE | www.plosone.org 8 April 2011 | Volume 6 | Issue 4 | e19010
